Informatie:
Fout:
ID
28419
Beschrijving
Study part: Investigator/ Site Change (Unscheduled). A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Trefwoorden
Versies (1)
- 11-01-18 11-01-18 -
Houder van rechten
Roche
Geüploaded op
11 januari 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Investigator/ Site Change (Unscheduled) rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g
Investigator/ Site Change (Unscheduled)
- StudyEvent: ODM
Similar models
Investigator/ Site Change (Unscheduled)
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Subject Number
Item
Subject Number:
text
C2348585 (UMLS CUI [1])
Subject Initials
Item
Subject Initials:
text
C1997894 (UMLS CUI [1,1])
C2986440 (UMLS CUI [1,2])
C2986440 (UMLS CUI [1,2])
Date of report
Item
Report Date:
date
C1302584 (UMLS CUI [1])
Investigator Number
Item
Investigator Number:
text
C2826689 (UMLS CUI [1])
Site Number
Item
Site Number:
text
C2825164 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
Date of change
Item
Effective Date of Change:
date
C3889737 (UMLS CUI [1])